Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Tripeptides – e.g. – tripeptide thyroliberin – etc.
Reexamination Certificate
2007-06-05
2007-06-05
Lukton, David (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Tripeptides, e.g., tripeptide thyroliberin , etc.
C530S327000, C530S328000, C530S329000, C530S330000, C514S014800, C514S015800, C514S016700, C514S017400, C514S018700, C514S019300
Reexamination Certificate
active
09937150
ABSTRACT:
Disclosed herein are phenylalanine derivative compounds of the following formulain-line-formulae description="In-line Formulae" end="lead"?W—Y—(AA)n—Zin-line-formulae description="In-line Formulae" end="tail"?wherein Y is a phenylalanyl radical, AA is an amino acid, n is an integer of 1 to 15, and substituent variables W and Z are as described herein. The compounds can be used to inhibit SH2 binding with phosphoproteins, and to inhibit proliferation of tumor cells.
REFERENCES:
patent: 3906031 (1975-09-01), Carpino et al.
patent: 4394519 (1983-07-01), Carpino et al.
patent: 4879398 (1989-11-01), Getman et al.
patent: 5182263 (1993-01-01), Danho et al.
patent: 5200546 (1993-04-01), Burke, Jr. et al.
patent: 5272268 (1993-12-01), Toyoda et al.
patent: 5296608 (1994-03-01), Danho et al.
patent: 5369110 (1994-11-01), Schmidlin et al.
patent: 5457114 (1995-10-01), Stuber et al.
patent: 5463062 (1995-10-01), Hemmerle et al.
patent: 5491253 (1996-02-01), Stuk et al.
patent: 5508437 (1996-04-01), Danho et al.
patent: 5525733 (1996-06-01), Novack et al.
patent: 5580979 (1996-12-01), Bachovchin
patent: 5587372 (1996-12-01), Aszodi et al.
patent: 5612370 (1997-03-01), Atwal
patent: 5616776 (1997-04-01), Stuk et al.
patent: 5627283 (1997-05-01), St uber et al.
patent: 5646036 (1997-07-01), Schwall et al.
patent: 5679842 (1997-10-01), Kleiner
patent: 5686292 (1997-11-01), Schwall et al.
patent: 5688992 (1997-11-01), Burke et al.
patent: 5698731 (1997-12-01), Bosetti et al.
patent: 5707624 (1998-01-01), Nickoloff et al.
patent: 5710129 (1998-01-01), Lynch et al.
patent: 5710173 (1998-01-01), Tang et al.
patent: 5712395 (1998-01-01), App et al.
patent: 5753687 (1998-05-01), Mjalli et al.
patent: 5756817 (1998-05-01), Choi et al.
patent: 5773411 (1998-06-01), Wells et al.
patent: 5780496 (1998-07-01), Tang et al.
patent: 5786454 (1998-07-01), Waksman et al.
patent: 5789427 (1998-08-01), Chen et al.
patent: 5792771 (1998-08-01), App et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5824862 (1998-10-01), Hiyoshi et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5843997 (1998-12-01), Heinz et al.
patent: 5849510 (1998-12-01), Al-Obeidi et al.
patent: 5849693 (1998-12-01), Wells et al.
patent: 5849742 (1998-12-01), App et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5883110 (1999-03-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 5886195 (1999-03-01), Tang et al.
patent: 5891917 (1999-04-01), Tang et al.
patent: 5912183 (1999-06-01), Comoglio et al.
patent: 5922697 (1999-07-01), Lunney et al.
patent: 5935993 (1999-08-01), Tang et al.
patent: 5948658 (1999-09-01), Landry
patent: 5958957 (1999-09-01), Andersen et al.
patent: 5965558 (1999-10-01), Mjalli et al.
patent: 5972978 (1999-10-01), Andersen et al.
patent: 5981569 (1999-11-01), App et al.
patent: 5981755 (1999-11-01), Horwell et al.
patent: 6022696 (2000-02-01), Harding et al.
patent: 6037134 (2000-03-01), Margolis
patent: 6228986 (2001-05-01), Lanter et al.
patent: 6307090 (2001-10-01), Burke et al.
patent: 6410585 (2002-06-01), Larsen et al.
patent: WO 94/07913 (1994-04-01), None
patent: WO 95/11917 (1995-05-01), None
patent: WO 96/23813 (1996-08-01), None
patent: WO 97/08193 (1997-03-01), None
patent: 98/50421 (1998-11-01), None
patent: WO 99/11606 (1999-03-01), None
patent: WO 00/73326 (2000-12-01), None
Viallet (Lung Cancer 15 (3) 367-73, 1996).
Kemeny (Seminars in Oncology 21 (4 Suppl 7) 67-75, 1994).
Newton (Expert Opinion on Investigational Drugs 9 (12) 2815-29, 2000).
Giese (Journal of Cancer Research and Clinical Oncology 127 (4) 217-25, 2001).
Ragnhammar (Acta Oncologica 40 (2□3) 282-308, 2001).
Garattini (European Journal of Cancer 37 Suppl 8 S128-47, 2001).
Bardelli (Oncogene 18, 1139-1146, 1999).
Ye et al., “L-O-(2-Malonyl)tyrosine” A New Phosphotyrosyl Mimetic for the Preparation of Src Homology 2 Domain Inhibitory Peptides, J. Med. Chem. vol. 38, pp. 4270-4275, 1995.
Burke, Jr., et al., “4′-O-[2-(2-Fluoromalonyl)]-L-tyrosine: A Phosphotyrosyl Mimic for the Preparation of Signal Transduction Inhibitory Peptides”, J. Med. Chem., vol. 39, pp. 1021-1027, Mar. 1, 1996.
Schoepfer et al., “Structure-based Design of Peptidomimetic Ligands of Grb2-SH2 Domain”, Bioorganic & Medicinal Chemistry Letters 8, pp. 2865-2870, 1998.
Yao et al., “Potent Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands”, J. Med. Chem., vol. 42, pp. 25-35, 1999.
Gay et al., “Effect of Potent and Selective Inhibitors of the Grb2 SH2 Domain on Cell Motility”, The Journal of Biological Chemistry, vol. 274, pp. 23311-23315, Aug. 13, 1999.
Schoepfer et al., “Highly Potent Inhibitors of the Grb2-SH2 Domain”, Bioorganic & Medicinal Chemistry Letters 9, pp. 221-226, 1999.
Burke, Jr., et al., Monocarboxylic-Based Phosphotyrosyl Mimetics in the Design of Grb2 SH2 Domain Inhibitors, Bioorganic & Medicinal Chemistry Letters 9, pp. 347-352, 1999.
Gilmer et al., “Peptide Inhibitors of src SH3-SH2-Phosphorprotein Interactions”, The Journal of Biological Chemistry, vol. 269, pp. 31711-31719, Dec. 16, 1994.
Charifson et al., “Peptide Ligands of pp60c-srcSH2 Domains: A Thermodynamic and Structural Study”, Biochemistry, vol. 36, pp. 6283-6293, 1997.
Liu et al., “Synthesis of L-2,3,5,6-Tetrafluoro-4-(Phosphonomethyl) Phenylalanine, a Novel Non-Hydrolyzable Phosphotyrosine Mimetic and L-4-(Phosphonodifluoromethyl)Phenylalanine”, Tetrahedron Letters, vol. 38, pp. 1389-1392, 1997.
Cleland, “The Meerwein Reaction in Amino Acid Synthesis. II. An Investigation of Twenty-one Substituted Anilines”, The Journal of Organic Chemistry, Vo., 34, pp. 744-747, Mar. 1969.
Gao et al., Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands. 2. 4-(2-Malonyl)phenylalanine as a Potent Phosphotyrosyl Mimetic, J. Med. Chem., vol. 43, pp. 911-920, 2000.
Furet et al., Stucture-Based Desing and Synthesis of High Affinity Tripeptide Ligands of the Grb2-SH2 Domain, J. Med. Chem., vol. 41, pp. 3442-3449, 1998.
Tong et al., “Carboxymethyl-phenylalanine as a Replacement for Phosphotyrosine in SH2 Domain Binding”, The Journal of Biological Chemistry, vol. 273, pp. 20238-20242 Aug. 7, 1998.
Tulasne et al., “The Multisubstrate Docketing Site of the MET Receptor is Dispensable for MET-mediated RAS Signaling and Cell Scattering”, Molecular Biology of the Cell, vol. 10, pp. 551-565, Mar. 1999.
Kim et al., “Dual Signaling Role of the Protein Tyrosine Phosphotase SHP-2 in Regulating Expression of Acute-Phase Plasma Proteins by Interleukin-6 Cytokine Receptors in Hepatic Cells”, Molecular and Cellular Biology, vol. 19, pp. 5326-5338, Aug. 1999.
Nguyen et al., “Association of the Multisubstrate Docking Protein Gab1 with the Hepatocyte Growth Factor Receptor Requires a Functional Grb2 Binding Site Involving Tyrosine 1356”, The Journal of Biological Chemistry, vol. 272, pp. 20811-20819, Aug. 15, 1997.
Maina et al., “Uncoupling of Grb2 from the Met Receptor in Vivo Reveals Complex roles in Muscle Development”, Cell, vol. 87, pp. 531-542, Nov. 1, 1996.
Ponzetto et al., “Specific Uncoupling of GRB2 from the Met Receptor”, The Journal of Biological Chemistry, vol. 271, pp. 14119-14123, Jun. 14, 1996.
Ettmayer et al., “Structural and Conformational Requirements for High-Affinity Binding to the SH2 Domain of Grb2”, J. Med. Chem., vol. 42, pp. 971-980, 1999.
Royal et al., “Differential Requirement of Grb2 and P13-Kinase in HGF/SF-Induced Cell Motility and Tubulogenesis”, Journal of Cellular Physiology, vol. 173, pp. 196-201, 1997.
Gao et al., Biorg and Med Chem Lett. 10, 923-927 (2000).
Burke, Jr., et al., “Preparation of . . . Peptide Synthesis”, J. of Synthetic Organic Chem., No. 11, p. 1019, Nov. 11,1991.
Burke, Jr., et al., “Potent Inhibition o
Burke, Jr. Terrence R.
Gao Yang
Yang Dajun
Yao Zhu-jun
Georgetown University
Leydig Voit & Mayer Ltd
Lukton David
United States of America, represented by the Secretary, Departme
LandOfFree
Phenylalanine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenylalanine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylalanine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3830666